Trogenix

We are proud to be supported by Cancer Research UK (CRUK) Cancer Research Horizons as we work towards the clinic this year with our unique 'Trojan Horse' approach for treating aggressive cancers and our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus. ? We look forward to attending the Cancer Research Horizons Impact Club’s event this week in London on 20 March.

Our CEO Ken Macnamara will be in Milan, Italy attending #BIOEuropeSpring, taking place from 17-19 March. Please reach out to us via [email protected] if you’re attending the conference and would like to learn more about our Synthetic Super-Enhancer (SSE) platform, Odysseus, for treating aggressive cancers and our glioblastoma programme which will soon enter the clinic. #Trogenix

Pleased to have welcomed Amy Brown from BiotechTV at our offices to speak with our CEO Ken Macnamara yesterday to discuss our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, and our unique 'Trojan Horse' approach for treating aggressive cancers, along with our compelling preclinical data. https://lnkd.in/gd38hciH

Congratulations to our SAB member Tom Bird the broader team at Cancer Research UK Scotland Institute on their #Nature paper regarding new liver cancer model for liver cancer precision therapy. A tour de force! Great to now have the disease-relevant and immune-competent mouse models for hepatocellular carcinoma (HCC) that spans diverse subtypes! ? Trogenix is grateful to be working with Tom and the CRUK Scotland Institute team to validate our first-in-class gene therapy for HCC, thanks to the generous support of Innovate UK and Cancer Research UK (CRUK). ? To read the full paper in Nature, visit:?https://lnkd.in/ey2_gumu ? #CancerResearch #LifeSciences #Innovation #GeneTherapy #Trogenix

2024 has been an exciting year for us at Trogenix as we have successfully achieved all milestones in platform and asset development; positioning us ready to enter the clinic in 2025 with our lead programme: TGX-007. Read more: https://lnkd.in/d9ZRdTM4 We are committed in our mission to deliver groundbreaking therapies that address devastating diseases for patients, transforming the healthcare paradigm from chronic disease management to curative solutions.? ? Looking forward to what’s to come in 2025! ?? ? #Trogenix

As we advance our groundbreaking platform toward clinical development, we are so excited that Tay Salimullah has joined our Board of Directors, his first Board appointment since leaving Novartis Gene Therapies. His expertise spans drug development, pricing science, market access, and operational excellence in high-value healthcare solutions.? https://lnkd.in/eGJqM5H8 #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation #Appointment

We are excited to announce that Trogenix has emerged from stealth today, unveiling our breakthrough Synthetic Super-Enhancer (SSE) platform, Odysseus, for treating aggressive cancers: https://lnkd.in/eGJqM5H8 Founded by our CSO Steve Pollard and 4BIO Capital as a spinout from The University of Edinburgh, and led by CEO Ken Macnamara, Trogenix brings together synthetic biology, machine learning, gene therapy and precision targeting technologies to transform cancer treatment, from chronic disease management to potentially curative one-time treatments. Thank you to our investors 4BIO Capital, IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital for their support in our mission to revolutionise cancer treatment. #CancerResearch #Glioblastoma #Immunotherapy #GeneTherapy #SyntheticBiology #LifeSciences #Innovation